抗性高血压:疾病负担和新兴的治疗选择
John M Flack1, Michael G Buhnerkempe2, Kenneth Todd Moore3
1Department of Medicine, Division of General Internal Medicine, Hypertension Section, Southern Illinois University, Southern Illinois University School of Medicine, 801 North Rutledge Street, Carbondale, IL, 62702, USA. jflack47@siumed.edu.
耐性高血压 (RHT) 是不控制的血压,尽管多种药物. 新兴的治疗方法为管理这种具有挑战性的疾病提供了新的希望,特别是在高风险人群中.
科学领域:
- 心血管医学 心血管医学
- 腎臟病學 (nephrology) 是一種醫學.
- 药理学 药理学是指药理学的学科.
背景情况:
- 抗性高血压 (RHT) 影响了大量高血压患者.
- 了解RHT复杂的病理生理学对于有效的管理至关重要.
- RHT不成比例地影响非裔美国人,老年人以及糖尿病或慢性病 (CKD) 患者.
研究的目的:
- 为了定义抗性高血压 (RHT).
- 审查RHT病理生理学和疾病负担.
- 确定高血压管理的障碍,并突出新兴治疗方法.
主要方法:
- 关于RHT定义,病理生理学和治疗的文献综述.
- 分析当前的治疗策略和新兴的治疗选择.
- 确定患有RHT风险较高的患者群体.
主要成果:
- RHT被定义为不受控制的血压 (BP) ≥130/80毫米 despite ≥3-4抗高血压药物或控制的BP despite ≥4药物,包括利尿剂.
- 血压调节涉及复杂的系统,包括renin-angiotensin-aldosterone系统,交感神经系统等.
- 新兴疗法针对新的途径,如SGLT2抑制,矿物质皮质类受体对抗作用和双内甲蛋白受体对抗作用.
结论:
- 然而,RHT的负担仍然很大.
- 优化当前疗法和整合新疗法对于管理RHT至关重要.
- 解决高风险RHT患者的需求需要全面的治疗方法.
相关概念视频
Hypertension and Regulation of Blood Pressure
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
Antihypertensive Drugs: Direct Renin Inhibitors
Antihypertensive Drugs: Action of Diuretics


